Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection.

  title={Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection.},
  author={Pappanaicken R. Kumaresan and Pallavi V Raja Manuri and Nathaniel D Albert and Sourindra N. Maiti and Harjeet Singh and Tiejuan Mi and Jason Roszik and Brian A. Rabinovich and Simon Olivares and Janani Krishnamurthy and Ling Li Zhang and Amer M. Najjar and M. Helen Huls and Amanda J Lee and Richard E. Champlin and Dimitrios P Kontoyiannis and Laurence J. N. Cooper},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  volume={111 29},
Clinical-grade T cells are genetically modified ex vivo to express chimeric antigen receptors (CARs) to redirect their specificity to target tumor-associated antigens in vivo. We now have developed this molecular strategy to render cytotoxic T cells specific for fungi. We adapted the pattern-recognition receptor Dectin-1 to activate T cells via chimeric CD28 and CD3-ζ (designated "D-CAR") upon binding with carbohydrate in the cell wall of Aspergillus germlings. T cells genetically modified with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 13 times over the past 90 days. VIEW TWEETS
29 Citations
52 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 29 extracted citations


Publications referenced by this paper.
Showing 1-10 of 52 references

Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood

  • MH Huls
  • J Vis Exp (72):e50070
  • 2013

Tethered IL-15 mutein on CD19-specific T cells sustains persistence when tumor antigen is low and can treat minimal residual disease

  • LV Hurton
  • Mol Ther 21:S237–S237
  • 2013

Similar Papers

Loading similar papers…